HansBiomed Corporation

KOSDAQ:A042520 Stock Report

Market Cap: ₩455.2b

HansBiomed Future Growth

Future criteria checks 5/6

HansBiomed is forecast to grow earnings and revenue by 183.9% and 28% per annum respectively.

Key information

183.9%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth42.0%
Revenue growth rate28.0%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Nov 2025

Recent future growth updates

No updates

Recent updates

There's No Escaping HansBiomed Corporation's (KOSDAQ:042520) Muted Revenues Despite A 25% Share Price Rise

Nov 02
There's No Escaping HansBiomed Corporation's (KOSDAQ:042520) Muted Revenues Despite A 25% Share Price Rise

HansBiomed Corporation (KOSDAQ:042520) Held Back By Insufficient Growth Even After Shares Climb 32%

Sep 11
HansBiomed Corporation (KOSDAQ:042520) Held Back By Insufficient Growth Even After Shares Climb 32%

Is HansBiomed (KOSDAQ:042520) Using Too Much Debt?

Apr 09
Is HansBiomed (KOSDAQ:042520) Using Too Much Debt?

HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement

Dec 09
HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement

Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Oct 29
Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Is HansBiomed (KOSDAQ:042520) A Risky Investment?

Feb 29
Is HansBiomed (KOSDAQ:042520) A Risky Investment?

HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth

Feb 29
HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth

Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Apr 10
Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?

Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

Mar 06
Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?

HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

Jan 30
HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.

Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Dec 08
Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?

Nov 20
Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?

Earnings and Revenue Growth Forecasts

KOSDAQ:A042520 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2026118,30010,3003,3004,3001
9/30/202588,300-6,400-8002001
6/30/202585,575-9,968-3,802-1,636N/A
3/31/202584,356-6,622-2,986-553N/A
12/31/202480,653-7,507-3,328-496N/A
9/30/202481,137-7,223-1,0701,759N/A
6/30/202480,639-9,493-9711,559N/A
3/31/202478,291-10,002-2,047221N/A
12/31/202378,321-19,694-4,719-2,803N/A
9/30/202378,032-23,045-5,805-3,733N/A
6/30/202378,561-9,852-6,519-4,015N/A
3/31/202380,309-9,968-6,436-3,937N/A
12/31/202276,9913,152-6,427-3,548N/A
9/30/202274,4596,147-8,404-4,270N/A
6/30/202268,200-10,348-12,602-7,403N/A
3/31/202263,498-11,639-14,734-8,981N/A
12/31/202158,284-22,373-18,536-12,802N/A
9/30/202159,098-18,289-19,622-14,645N/A
6/30/202170,297-25,593-12,475-6,067N/A
3/31/202173,649-23,626-11,138-4,052N/A
12/31/202080,678-16,686-5,7592,051N/A
9/30/202080,098-17,840-2,2225,751N/A
6/30/202072,2935,259-2,5743,791N/A
3/31/202071,3957,539-6,3648,884N/A
12/31/201969,0439,867-8,8736,536N/A
9/30/201966,9919,951-8,0277,714N/A
6/30/201964,7685,521-8,8545,855N/A
3/31/201961,5015,253N/A3,193N/A
12/31/201856,9454,508N/A6,605N/A
9/30/201851,7464,159N/A5,204N/A
6/30/201846,8666,757N/A2,147N/A
3/31/201842,2975,623N/A1,871N/A
12/31/201739,9776,150N/A4,757N/A
9/30/201739,0587,828N/A5,597N/A
6/30/201737,2696,660N/A7,747N/A
3/31/201734,6116,756N/A5,011N/A
12/31/201632,2966,373N/A1,200N/A
9/30/201629,0484,625N/A626N/A
6/30/201627,4944,911N/A2,592N/A
3/31/201626,3375,364N/A5,315N/A
12/31/201524,1184,856N/A4,505N/A
9/30/201523,4284,909N/A4,408N/A
6/30/201523,0054,271N/A4,460N/A
3/31/201522,7263,878N/A3,074N/A
12/31/201421,4513,621N/A1,928N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A042520 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3%).

Earnings vs Market: A042520 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A042520 is expected to become profitable in the next 3 years.

Revenue vs Market: A042520's revenue (28% per year) is forecast to grow faster than the KR market (10.4% per year).

High Growth Revenue: A042520's revenue (28% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A042520's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/24 19:35
End of Day Share Price 2025/11/24 00:00
Earnings2025/06/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HansBiomed Corporation is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jong Kyung ChoiDAOL Investment & Securities Co., Ltd.
Sang-Hun LeeiM Securities
Se Hoon SohnNH Investment & Securities Co., Ltd.